Aptose Biosciences (TSE:APS) Shares Cross Above 50 Day Moving Average – Here’s Why

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s share price passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$2.18 and traded as high as C$2.19. Aptose Biosciences shares last traded at C$2.18, with a volume of 18,264 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Alliance Global Partners downgraded Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Aptose Biosciences Price Performance

The company has a debt-to-equity ratio of -97.77, a current ratio of 0.53 and a quick ratio of 5.41. The company has a market cap of C$5.49 million, a PE ratio of 3.12 and a beta of -1.05. The company has a 50-day moving average price of C$2.18 and a two-hundred day moving average price of C$1.98.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.